and presented an overview of vaccine strategies for AI vaccine, including development of immunogenicity, vaccine safety, and cross-protective vaccines for controlling HPAIs in poultry.
Current Epidemiology of HPAI in South Korea

H5N1 HPAI in Korea
Since the first identification of the H5 subtype HPAI virus A/ goose/Guangdong/1/1996 (H5N1) in 1996 in China, these viruses have evolved into diverse lineages as well as reassortants, generating H5N2, H5N3, H5N5, H5N6, and H5N8 [14] [15] [16] strains. Although the HA cleavage site in the HA protein is known to be critical for viral pathogenicity in avian species [17] , only the H5 and H7 subtypes of AI viruses are highly pathogenic for poultry.
In Korea, the first outbreak of H5N1 HPAI caused the 2003-2004 epidemic in poultry farms with high mortality [18, 19] . Since then, second and third outbreaks of H5N1 HPAI occurred in 2006 and 2008, respectively. The HPAI outbreak in 2008 spread to 11 provinces and affected not only the poultry farms but also diverse bird species in live bird markets [20] . Based on the sequence of the gene encoding HA, the H5N1 HPAIVs of the 2008 Korean epidemic belong to clade 2.3.2, unlike those of the 2003 (clade 2.5) and 2006 (clade 2.2) outbreaks [20, 21] .
Following the detection of the H5N1 HPAIV in migratory birds in 2010, a fourth outbreak of the virus was inevitable, and around fourteen bird species, including poultry and wild bird were affected [22] . Although the H5N1 HPAIVs of the 2010 outbreak were clustered into clade 2.3.2, they were not closely related to the H5N1 HPAIV of 2008.
The causative AI viruses of the four HPAIV outbreaks between 2003 and 2011 belonged to the H5N1 subtypes; however, phylogenetic relationship indicated that the viruses belonged to different lineages. Therefore, from the epidemiological point of view, these strains were introduced from abroad, rather than evolving by persistent circulation inside the country.
H5N8 HPAI in Korea
An outbreak of a novel subtype of the HPAIV progressed between January 16 and May 8, 2014, as phases I, II, and III [23] . The causative AI viruses were reported to be novel reassorted influenza A (H5N8) viruses of clade 2.3.4.6, which was later more frequently called clade 2.3.4.4 [24, 25] . Following an outbreak in poultry in South Korea in January 2014, the H5N8 viruses rapidly spread worldwide in 2014-2015, and long-distance migratory birds played a major role in the global dissemination of these viruses [26] . In addition, since the first outbreak of the H5N8 viruses in early 2014, these viruses were reintroduced into Korea by the migratory waterfowl in 2014-2015 [27] , and have caused sporadic outbreaks of HPAI in Korea ever since 2014.
In the experimental infection study, the viral replication and shedding were greater in H5N8-infected ducks than in H5N1-infected ducks [28] , and it had lower pathogenicity and transmissibility in poultry species compared to the previously reported H5N1 HPAIVs [29] . These characteristics of H5N8 viruses might lead to late recognition of the symptoms associated with HPAI and increase the chances of viral transmission among poultry farms. However, the transmission mechanism of the HPAIVs is still not fully understood. Further studies on risk factors in terms of biosecurity of poultry farms and transmission ecology of the virus in migratory and indigenous animals are required [30] .
H5N6 HPAI in Korea
A reassortant clade 2.3.4.4 of the H5N6 HPAIVs was isolated from migratory birds in South Korea during October and November 2016 [8, 27] . Subsequently, HPAI outbreaks in approximately 380 poultry farms were reported by April 4th, 2017, in South Korea (http://www.qia.go.kr). The H5N6 HPAIVs were first reported in China in 2013, which disseminated not only within China but also in Vietnam and Laos [31, 32] . While the first Chinese H5N6 viruses were novel reassortants of NA from the H6N6 viruses and seven other genes from H5N1 viruses, the Korean H5N6 HPAIVs were novel reassortants of Chinese H5N6 viruses and Eurasian low pathogenicity AI viruses of wild birds [14] .
The recently emerging H5N6 HPAIVs in Korea are continuously evolving and are found in wild migratory birds [33] . Since the H5N6 HPAIVs are also related to human infections [34] , additional studies on their pathogenicity, interspecies transmission, and potential risk for public health and poultry industries are required.
Perspective on HPAI in Korea
The HPAIVs identified since 2003 are all H5-subtype viruses that are genetically distant from each other, and most of them were introduced from outside Korea ( Table 1 ). The continuous HPAI outbreaks by novel H5Nx viruses in Korea is closely related to migratory birds, and most HPAIV strains are genetically similar to those from China and Southeast Asian countries [18, [26] [27] [28] AI viruses occur in live poultry markets of China, which might result in the emergence of diverse AI viruses in China [31] , future outbreaks of HPAI by other novel HPAIVs may be inevitable in Korea. Therefore, monitoring Chinese HPAIVs and predicting the HPAIV lineages that can be introduced to Korea is one of the strategies for controlling future HPAI epidemics. This can be accomplished with the recent advance in bioinformatics, which can predict evolution of strains from the shape of genealogical trees [35] . Using this approach, we collected HA sequences of Chinese H5-subtype influenza viruses and predicted lineages with high fitness in a preliminary study (Fig. 1) . Two lineages, including the H5N2, H5N6, and H5N8 viruses of the 2014 outbreaks, were inferred to have high fitness, and the Korean H5N6 HPAIV (2016) belonged to one of those lineages, showing 97.5%-98.4% amino acid similarities. This preliminary result indicates that the fitness inference tool developed by Neher et al. [35] can be applied to study the molecular epidemiology of HPAIVs.
In addition, continuous monitoring of migratory birds and indigenous animals should be conducted to understand the interspecies transmission ecology of HPAIVs. Although the global transmission of these viruses is closely associated with migratory birds, their mode of transmission from migratory birds to poultry farms is not known. While poultry farm-based risk factors of HPAI outbreaks might be important as management factors, ecological risk factors can be also investigated considering interspecies transmission of influenza viruses [29] . In our monitoring system, several indigenous avian and mammalian species showed serological evidence of H5-subtype influenza virus infections (unpublished data). Therefore, consideration of both biosecurity of poultry farms and the transmission ecology of HPAIVs in different hosts can provide Clade definition in the first reports [24, 25] . additional information for the development of control policies.
Current HPAI H5 Vaccine
HPAIVs are economically important diseases of poultry. In particular, highly pathogenic subtypes of the H5 and H7 AI viruses cause devastating mortality in poultry industries, reduce egg production, and decrease bird weight gain. Unfortunately, the AI viruses are able to infect humans, which cause severe diseases with high mortality rates and are a cause of serious public health concern [36, 37] . Therefore, many scientists suggest vaccination as one of the effective methods for prevention of AI virus infection. Conventional AI vaccines, which are based on inactivated whole viruses [38] from an HPAI outbreak or a low pathogenicity isolate with a well-matched HA, have been shown to be effective at preventing clinical disease and decreasing virus shed. The first HPAI vaccine manufactured in China used the inactivated low pathogenic AI H5 virus A/Turkey/England/N-28/1973 (H5N2) and rapidly controlled the H5N1 outbreaks in China in 2004 [39] . However, the seed virus of the inactivated H5N2 vaccine was limited to the control of antigenic diversity within the H5N1 strains of China. To circumvent this problem, an advanced H5 vaccine using HA and NA from the Re-1 strain of H5N1 (A/goose/Guangdong/ 1/1996) and 6 internal genes from A/Puerto Rico/8/1934 (PR8) was produced using reverse genetics, which was antigenically well-matched with the epidemic strains of that time [40, 41] . The inactivated vaccines used in China were also exported to several other countries, including Egypt, Indonesia, Vietnam, Bangladesh, Burma, and Mongolia for effective control of H5N1 HPAIVs [42] .
To control H5 HPAIV epidemics, vaccine candidates are continuously improved and developed using a recombinant virus based on modified HA and NA, which is designated as H5N1/PR8 (2+6) ( Table 2) [39, 43, 44] . However, since 2010, H5 AI virus with other NA subtypes including N2, N3, N6, and N8 have been detected in poultry and wild birds in China, which may have contributed to the spread of H5N8 viruses to North America, Europe, and neighboring Asian countries [4, 5, 12, 26] . Therefore, to improve vaccine efficacy against the newly emerging or re-emerging H5 HPAIVs in poultry, it is necessary to develop or induce a bigger spectrum of protective immunity.
Generation of Novel AI Vaccines
Recombinant virus vector-based vaccines
Recombinant virus vector-based vaccines can express any antigen with or without modification in vivo [45] . Previous reports suggest that recombinant virus vector vaccines can stimulate a wide range of immune responses compared to conventional inactivated vaccines [46] [47] [48] . So far, a variety of recombinant H5N1 influenza vaccines have been developed using fowl pox virus, Newcastle disease virus (NDV), Turkey herpes virus, duck enteritis virus, and infectious laryngotracheitis virus. In particular, a recombinant NDV vector-based H5N1 AI vaccine was approved for use in chickens in China and the bivalent recombinant NDV vector-based H5N1 AI vaccine was manufactured and used in chickens in China between 2006 and 2012 [49] [50] [51] . To improve the NDV vaccine efficacy, researchers are not only inducing AI-specific immune response to protect against viral infection, but are also considering the limitations of anti-NDV antibodies derived from routine NDV vaccination [52, 53] .
Nucleic acid-based vaccines
DNA vaccines offer a number of advantages over conventional vaccines [54] . For example, an administered DNA vaccine can elicit both humoral and cellular immunity and can be administered multiple times to enhance immune efficacy. Several studies showed that protection of highly pathogenic H5 virus-infected chickens or mammals was improved by codon optimization of DNA vaccines based on H5N1 HAs [55] [56] [57] DNA vaccines are usually constructed based on the HA of the matching subtype; however, recent studies demon- strated that vaccines can be developed as a mixture expressing HA from different clades of H5N1 viruses, and this new DNA vaccine candidate could protect chickens challenged with heterologous H5N1 viruses [57] . However, despite positive results regarding vaccine efficacy, the use of DNA vaccines for vaccination of poultry is still limited by the expenses of mass vaccination and the requirement of devices for efficient on-site vaccination such as jet injection [58] and electroporation [59] . Although licensed DNA vaccines against AI for poultry are currently unavailable, several DNA vaccine candidates are being studied for providing protection against HPAIVs in poultry.
Recombinant protein vaccines
The use of current conventional egg-based H5 AI vaccines are limited by subtype-specific vaccine efficacy and long period of vaccine production (approximately 6 months) [38] . Therefore, previous studies have suggested the use of recombinant protein vaccines based on bacterial [60] , mammalian [61] , and recombinant baculovirus/insect cell expression system [62] for controlling HPAIVs. Among the viral proteins of H5 AI viruses, the HA and matrix protein 2 ectodomains (M2e) have been developed as candidate antigens for recombinant protein vaccines [60, 62, 63] .
HA is an envelope glycoprotein and it is best-suited for inducing the production of neutralizing antibodies. Thus, to control H5 HPAIVs, HA is being developed predominantly using several recombinant expression systems [64] [65] [66] . Saczynska [66] and Liu et al. [67] used bacterial and baculoviral systems, respectively, for expressing HA of H5N1. These studies demonstrated that HA was able to induce antigen-specific neutralizing antibody response and vaccinated chickens could be protected against the highly pathogenic H5 influenza virus.
Matrix 2 (M2) is transmembrane protein and it plays key roles in viral replication and structural integrity [68, 69] . The extracellular domain of M2 (M2e) consists of 24 amino acids and it is one of the highly conserved domains across different subtypes of influenza viruses. Thus, M2e is one of the candidates for developing a universal influenza vaccine [70, 71] . The M2e vaccine candidates have induced immune responses and protective efficacy against highly pathogenic H5N1 viruses in chickens [72, 73] . However, several studies showed that M2e has lower immunogenicity, and therefore, requires carrier proteins [74, 75] and co-administration with vaccine adjuvants such as water-in-oil based adjuvants [76] for inducing antigen-specific immunogenicity.
Universal vaccines
Universal vaccines provide broad cross-protective immunity than the currently licensed vaccines and should provide longer protection against several relevant influenza viruses. The globular head domain of HA plays a critical role in producing potent neutralizing antibodies, which indicates that HA can induce the production of neutralizing antibodies against only homologous viruses [1, 77] . Therefore, many investigators demonstrated that highly conserved sequences such as the stem region of HA (called HA2) and M2e are more desirable targets for generating a universal vaccine [78] [79] [80] . Consist with the above results, our group also confirmed that the HA2 domain induced the production of a broad spectrum of neutralizing activities against different avian strains containing H5 subtypes (unpublished). In addition, recent studies demonstrated that different combinations of vaccines increased the efficacy of universal vaccines. The prime-boost strategy with plasmid DNA and other vaccine candidates such as virus-like particle [81] and inactivated viruses [82] increased neutralizing activities with homologous and heterologous viruses. Thus, strategies involving recombinant proteins and combinatorial vaccines should be developed for generating effective and safe universal influenza vaccines.
Conclusion
Nowadays, sub-lineages of influenza H5 virus are rapidly evolving and they are considered to be the most likely cause of infectious outbreaks in poultry. Recently, the outbreak of the novel and highly pathogenic H5N6 and H5N8 AI virus was reported in poultry in South Korea. These viruses belong to clade 2.3.4.4 and showed a close relationship with HPAIs identified from Eastern China and South Korea. However, the route of virus dissemination is still unclear. Therefore, these concerns collectively call for continued virus monitoring, surveillance of poultry and wild birds, and characterization and pathogenicity assessment of these viruses, the information pertaining to which should be made available before any outbreak in poultry.
To protect against novel H5 HPAIs in poultry and to overcome the limitations of conventional vaccines, we attempted to develop new vaccine candidates with broad cross-protectivity against influenza viruses. However, H5 HPAI vaccination is still a complex issue considering scientific regulations and policies of vaccine application in the field. 
